Dossier
web
observational
Patients With MPNs Face Higher Cardiovascular Risks, in Addition to AML Risk
Key claim: PV and ET patients have 14.3- and 26.3-fold higher observed risk of death from myeloid malignancies than the general population, with particularly high cardiovascular and cerebrovascular mortality.
Abstract
Both PV and ET patients were at 14.3- and 26.3-fold higher observed risk of death from myeloid malignancies compared to the general population, with particularly high cardiovascular and cerebrovascular risks in PV and ET patients.
Why this matters
PV and ET patients have 14.3- and 26.3-fold higher observed risk of death from myeloid malignancies than the general population, with particularly high cardiovascular and cerebrovascular mortality.